Goudarzi Mehdi, Seyedjavadi Sima Sadat, Goudarzi Hossein, Mehdizadeh Aghdam Elnaz, Nazeri Saeed
Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Science, Tehran, Iran.
Department of Pharmaceutical Biotechnology, Pasteur Institute of Iran (IPI), No. 358, 12th Farwardin Avenue, Jomhhoori Street, Tehran 1316943551, Iran.
Scientifica (Cairo). 2014;2014:916826. doi: 10.1155/2014/916826. Epub 2014 Jun 1.
The incidence and mortality rate of Clostridium difficile infection have increased remarkably in both hospital and community settings during the last two decades. The growth of infection may be caused by multiple factors including inappropriate antibiotic usage, poor standards of environmental cleanliness, changes in infection control practices, large outbreaks of C. difficile infection in hospitals, alteration of circulating strains of C. difficile, and spread of hypervirulent strains. Detection of high-risk populations could be helpful for prompt diagnosis and consequent treatment of patients suffering from C. difficile infection. Metronidazole and oral vancomycin are recommended antibiotics for the treatment of initial infection. Current treatments for C. difficile infection consist of supportive care, discontinuing the unnecessary antibiotic, and specific antimicrobial therapy. Moreover, novel approaches include fidaxomicin therapy, monoclonal antibodies, and fecal microbiota transplantation mediated therapy. Fecal microbiota transplantation has shown relevant efficacy to overcome C. difficile infection and reduce its recurrence.
在过去二十年中,艰难梭菌感染的发病率和死亡率在医院和社区环境中均显著上升。感染的增加可能由多种因素引起,包括抗生素使用不当、环境卫生标准差、感染控制措施的变化、医院内艰难梭菌感染的大规模暴发、艰难梭菌流行菌株的改变以及高毒力菌株的传播。检测高危人群有助于对艰难梭菌感染患者进行及时诊断和后续治疗。甲硝唑和口服万古霉素是治疗初始感染的推荐抗生素。目前艰难梭菌感染的治疗包括支持治疗、停用不必要的抗生素以及特异性抗菌治疗。此外,新的治疗方法包括非达霉素治疗、单克隆抗体和粪便微生物群移植介导的治疗。粪便微生物群移植已显示出克服艰难梭菌感染并降低其复发率的相关疗效。